Table 2.
Reasons for SRI(4) response at week 52 in TULIP-1 among BICLA non-responders/SRI(4) responders
| SLEDAI-2K domain, n (%) | BICLA non-responders/SRI(4) responder in TULIP-1 | |
| Placebo (n=28) |
Anifrolumab 300 mg (n=12) |
|
| Arthritis | 22 (78.6) | 6 (50.0) |
| Arthritis only | 7 (25.0) | 0 |
| Arthritis+other items | 15 (53.6) | 6 (50.0) |
| Rash | 1 (3.6) | 2 (16.7) |
| Rash+other items | 1 (3.6) | 2 (16.7) |
| Proteinuria | 2 (7.1) | 2 (16.7) |
| Proteinuria only | 1 (3.6) | 0 |
| Proteinuria+other items | 1 (3.6) | 2 (16.7) |
| Mucosal ulcers+anti-dsDNA | 0 | 1 (8.3) |
| Mucosal ulcers+low complement | 1 (3.6) | 0 |
| Alopecia+low complement+leucopenia | 0 | 1 (8.3) |
| Vasculitis+low complement | 1 (3.6) | 0 |
| Anti-dsDNA antibodies+low complement | 1 (3.6) | 0 |
anti-dsDNA, anti-double-stranded DNA; BICLA, British Isles Lupus Assessment Group-based Composite Lupus Assessment; SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2000; SRI(4), Systemic Lupus Erythematosus Responder Index of ≥4.